Ascletis’s IFN-Free HCV Combo Set For Trials

25 Jun 2015

• By Ying Huang

China’s first home developed, interferon-free hepatitis C virus (HCV) treatment, a combination of two direct acting antiviral agents, is expected to enter new clinical trials in both China and Taiwan within a year.

SHANGHAI – A venture in China is moving ahead with new trials for an all-oral therapy for HCV, an infection estimated to affect more than 40 million people in the country.

Hangzhou, Zhejiang-based Ascletis Inc. has announced the filing of two clinical trial applications to the China Food and Drug...